Elan said yesterday it was in talks with potential partners to market its migraine drug Frovelan in the United States. Chief financial officer Mr Thomas Lynch said peak sales of $300-$350 million were expected for the drug with a partner, roughly double sales if Elan relied on its own resources. He said Elan expected Food and Drug Administration approval to launch Frovelan in September.